Details

Autor(en) / Beteiligte

• Rusert, Peter
• Kouyos, Roger D
• Kadelka, Claus
• Ebner, Hanna
• Schanz, Merle
• Huber, Michael
• Braun, Dominique L
• Hozé, Nathanael
• Scherrer, Alexandra
• Magnus, Carsten
• Weber, Jacqueline
• Uhr, Therese
• Cippa, Valentina
• Thorball, Christian W
• Kuster, Herbert
• Cavassini, Matthias
• Bernasconi, Enos
• Hoffmann, Matthias
• Calmy, Alexandra
• Battegay, Manuel
• Rauch, Andri
• Yerly, Sabine
• Aubert, Vincent
• Klimkait, Thomas
• Böni, Jürg
• Fellay, Jacques
• Regoes, Roland R
• Günthard, Huldrych F
• Trkola, Alexandra

Titel

Determinants of HIV-1 broadly neutralizing antibody induction

Ist Teil von

• Nature medicine, 2016-11, Vol.22 (11), p.1260-1267

Ort / Verlag

United States: Nature Publishing Group

Erscheinungsjahr

2016

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Broadly neutralizing antibodies (bnAbs) are a focal component of HIV-1 vaccine design, yet basic aspects of their induction remain poorly understood. Here we report on viral, host and disease factors that steer bnAb evolution using the results of a systematic survey in 4,484 HIV-1-infected individuals that identified 239 bnAb inducers. We show that three parameters that reflect the exposure to antigen-viral load, length of untreated infection and viral diversity-independently drive bnAb evolution. Notably, black participants showed significantly (P = 0.0086-0.038) higher rates of bnAb induction than white participants. Neutralization fingerprint analysis, which was used to delineate plasma specificity, identified strong virus subtype dependencies, with higher frequencies of CD4-binding-site bnAbs in infection with subtype B viruses (P = 0.02) and higher frequencies of V2-glycan-specific bnAbs in infection with non-subtype B viruses (P = 1 × 10 ). Thus, key host, disease and viral determinants, including subtype-specific envelope features that determine bnAb specificity, remain to be unraveled and harnessed for bnAb-based vaccine design.